Goldman Sachs Forecasts Significant Upside for Novo Nordisk Shares

Novo Nordisk DK0062498333

Shares of Novo Nordisk experienced substantial gains on Thursday following a major price target revision from Goldman Sachs. The Danish pharmaceutical giant is riding momentum from the promising launch of its oral Wegovy tablet, though analyst sentiment on the stock remains divided.

The investment community is split on Novo Nordisk's prospects. This disparity is highlighted by the wide range of current price targets:
* Barclays maintains a "Neutral" stance with a 360 DKK target, close to the prevailing trading level.
* Jefferies surprisingly downgraded the equity to "Sell," issuing a 270 DKK target and citing valuation concerns.
* Goldman Sachs stands on the bullish end, reaffirming its "Buy" recommendation.

This spectrum of opinions underscores market uncertainty regarding the actual adoption rate of the new oral therapy. The stock's forward P/E ratio of 16.2x for 2025 estimates sits above the industry average, a premium that supporters argue is justified by expanded market potential.

Oral Wegovy Launch Drives Goldman's Bullish Case

In a significant update on Thursday morning, Goldman Sachs raised its price objective for Novo Nordisk from 352 DKK to 436 DKK, implying roughly 24% potential upside. Analyst James Quigley identified the recently introduced oral Wegovy tablet as a key near-term growth catalyst.

The drug's early performance supports this view: by mid-January, it had already reached approximately 3,100 patients. This rapid uptake occurred just two weeks after its commercial debut in early January 2026, following U.S. FDA approval of the 25-mg formulation on December 22, 2025.

The oral treatment strategically targets patients averse to injectable therapies. Its out-of-pocket cost is set at about $149 monthly for the starting dose, notably below the $350 price point typically negotiated by the government for state-funded programs.

Regulatory Delay and Reimbursement Challenges

Novo Nordisk has gained an additional, temporary advantage. The FDA postponed its decision on Eli Lilly's competing oral drug, Orforglipron, from late March to April 10, 2026. This grants the Danish firm an exclusive head start in the lucrative oral GLP-1 medication segment.

However, insurance coverage remains a persistent hurdle. Pennsylvania's decision to halt Medicaid coverage for weight-loss medications starting January 2026 exemplifies the ongoing tension between strong patient demand and payer willingness to provide reimbursement.

The coming weeks are critical. Finalized January prescription data will reveal whether the product launch is building sustainable momentum. Subsequently, the company's fourth-quarter earnings report should clarify whether the optimistic thesis from Goldman Sachs or the cautious stance from Jefferies is warranted.